Foghorn Therapeutics Inc. Gain (Loss) on Extinguishment of Debt
Foghorn Therapeutics Inc. (FHTX) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-03-09
- Foghorn Therapeutics Inc. gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
- Foghorn Therapeutics Inc. gain (loss) on extinguishment of debt for fiscal 2021 was -$1.23M.
- Foghorn Therapeutics Inc. gain (loss) on extinguishment of debt for fiscal 2020 was -$222.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 1 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2021-12-31 | -$1.20M 10-K/A · filed 2022-08-09 | -$1.23M 10-K · filed 2023-03-09 |
| 2020-12-31 | -$222.00K 10-K/A · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |